Skip to main content

and
  1. No Access

    Article

    Structure-guided combination therapy to potently improve the function of mutant CFTRs

    Available corrector drugs are unable to effectively rescue the folding defects of CFTR-ΔF508 (or CFTR-F508del), the most common disease-causing mutation of the cystic fibrosis transmembrane conductance regula...

    Guido Veit, Hai** Xu, Elise Dreano, Radu G. Avramescu, Miklos Bagdany in Nature Medicine (2018)

  2. Article

    Open Access

    Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening

    MYC family members are among the most frequently deregulated oncogenes in human cancers, yet direct therapeutic targeting of MYC in cancer has been challenging thus far. Synthetic lethality provides an opportu...

    Zongxiang Zhou, Manishha Patel, Nicholas Ng, Mindy H Hsieh, Anthony P Orth in BMC Cancer (2014)